Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $263.96 -0.02%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
Revenue Growth %: +9.7%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
Revenue Growth %: +9.7%
Join SI Premium – FREE
Susquehanna option strategist Alison Edwards notes call buying in AbbVie (NYSE: ABBV) ahead of various drug trials, as investors purchased Nov 91 Calls with roughly 7,500 trading for $1.25, targeting 3% upside into mid-Nov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie presents real-world Vraylar data at Psych Congress 2026
- Boeing (BA) call put ratio 1.8 calls to 1 put into events
- Alibaba (BABA) call put ratio 2.4 calls to 1 put as share price up 3% into President Donald Trump and Chinese President Xi Jinping's summit
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
